Modality
Vaccine
MOA
PD-L1i
Target
EZH2
Pathway
DDR
CKD
Development Pipeline
Preclinical
~Jul 2016
→ ~Oct 2017
Phase 1
Jan 2018
→ Jul 2028
Phase 1Current
NCT03151324
600 pts·CKD
2018-01→2026-10·Completed
NCT03070784
1,973 pts·CKD
2019-07→2028-07·Recruiting
2,573 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-10-267mo awayInterim· CKD
2028-07-022.3y awayInterim· CKD
Trial Timeline
2018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3
P1
Complet…
P1
Recruit…
Catalysts
Interim
2026-10-26 · 7mo away
CKD
Interim
2028-07-02 · 2.3y away
CKD
RecruitingCompleted|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03151324 | Phase 1 | CKD | Completed | 600 | HbA1c |
| NCT03070784 | Phase 1 | CKD | Recruiting | 1973 | EFS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-1085 | Pfizer | Preclinical | FXIa | |
| Rilulemzoparlimab | Novartis | Phase 2/3 | KRASG12D | |
| SNY-9600 | Sanofi | NDA/BLA | B7-H3 | |
| Nirafutibatinib | Bayer | Phase 2 | WRN | |
| DSN-2247 | Daiichi Sankyo | NDA/BLA | EZH2 | |
| Motainavolisib | Amgen | NDA/BLA | CD47 | |
| BNT-8090 | BioNTech | Phase 2 | AuroraA | |
| Miriglumide | Alnylam | Phase 3 | CD3 | |
| SRP-1135 | Sarepta | Phase 2/3 | MDM2 | |
| HAL-9635 | Halozyme | Phase 2/3 | EZH2 |